2021
Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms
Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice 2021, 18: 140-147. PMID: 34558297, PMCID: PMC9213200, DOI: 10.1200/op.21.00466.Peer-Reviewed Original ResearchConceptsCancer-associated symptomsChemotherapy-induced peripheral neuropathyCancer-associated fatigueSymptom control drugsPatient-clinician discussionsExocrine pancreatic insufficiencyCost of drugsBrand-name formulationProphylaxis regimenPeripheral neuropathyDrug prescribedPancreatic insufficiencyNew agentsControl drugSame drugFinancial toxicitySymptomsDrugsFinancial burdenRelevant guidelinesAnticancer drugs
2020
Low serum trypsinogen levels in chronic pancreatitis: Correlation with parenchymal loss, exocrine pancreatic insufficiency, and diabetes but not CT-based cambridge severity scores for fibrosis
Zhan W, Akshintala V, Greer PJ, Greer JB, Alkaade S, Anderson MA, Muniraj T, Papachristou GI, Sandhu BS, Slivka A, Wilcox CM, Bellin MD, Singh VK, Yadav D, Brand RE, Whitcomb DC, Group F. Low serum trypsinogen levels in chronic pancreatitis: Correlation with parenchymal loss, exocrine pancreatic insufficiency, and diabetes but not CT-based cambridge severity scores for fibrosis. Pancreatology 2020, 20: 1368-1378. PMID: 32967795, DOI: 10.1016/j.pan.2020.08.025.Peer-Reviewed Original ResearchConceptsSerum trypsinogen levelsChronic pancreatitisTrypsinogen levelsAcinar cell functionCP patientsParenchymal lossCell functionComplex inflammatory disorderExocrine pancreatic insufficiencyCT-based criteriaNAPS2 studySerum trypsinogenAcinar cell lossSurgical resectionFinal cohortInflammatory cellsInflammatory disordersControl subjectsSeverity scoreClinical managementPancreatic insufficiencyStellate cellsNormal rangeCell lossIslet cells
2002
A patient with autoimmune hepatitis type I, Addison's disease, atrophic thyroiditis, atrophic gastritis, exocrine pancreatic insufficiency, and heterozygous α1-antitrypsin deficiency
Bergwitz C, Trautwein C, Brabant G, Manns MP. A patient with autoimmune hepatitis type I, Addison's disease, atrophic thyroiditis, atrophic gastritis, exocrine pancreatic insufficiency, and heterozygous α1-antitrypsin deficiency. The American Journal Of Gastroenterology 2002, 97: 1050. PMID: 12003388, DOI: 10.1111/j.1572-0241.2002.05628.x.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionAtrophic gastritisAutoimmune hepatitisAddison's diseaseAlcohol consumptionAssociation of autoimmune hepatitisAutoimmune hepatitis type IHeterozygous alpha1-antitrypsin deficiencyHeterozygous α1-Antitrypsin DeficiencyHistory of Addison's diseaseSerum alpha1-antitrypsin levelsDiagnosis of autoimmune hepatitisDecompensated liver cirrhosisDevelopment of cirrhosisSevere atrophic gastritisAdditional risk factorsAlpha1-antitrypsin deficiencyAlpha1-antitrypsin levelsΑ1-antitrypsin deficiencyAlpha1-antitrypsin geneExocrine pancreatic insufficiencyAtrophic thyroiditisHydrocortisone therapyAdrenal insufficiencyLiver biopsyTowards the pharmacogenomics of cystic fibrosis
Sangiuolo F, DApice M, Bruscia E, Lucidi V, Novelli G. Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics 2002, 3: 75-87. PMID: 11966405, DOI: 10.1517/14622416.3.1.75.Peer-Reviewed Original ResearchConceptsCystic fibrosisPancreatic insufficiencyChronic obstructive lung diseaseRelated clinical diseasesObstructive lung diseaseElevated sweat chloride concentrationsExocrine pancreatic insufficiencySweat chloride concentrationCongenital bilateral absenceMultiorgan diseaseChronic pancreatitisClinical symptomsLung diseaseDrug therapyClinical diseaseClinical overlapRecessive genetic diseaseTherapeutic questionsBilateral absenceDrug efficacyDiseaseVas deferensTherapy approachesFibrosisSymptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply